HOME >> MEDICINE >> NEWS
New study shows patients more willing to consider self-injectable HIV therapy than many physicians anticipate

Initial results from the OpenMind study, the largest behavioural study to look at both patients' and physicians' perceptions of HIV care in treatment-experienced patients, were revealed today at EACS. The study's findings are anticipated to help physicians implement improved care to HIV patients and help pave the way for better acceptance and integration of other new innovative drugs such as monoclonal antibodies that are increasingly being developed for the management of HIV and other diseases.

The study was conceived to look at attitudes to FUZEON (enfuvirtide), the first approved HIV fusion inhibitor, and an important option for treatment-experienced patients who face HIV resistance. FUZEON presents unique challenges because it is the first self-injectable antiretroviral whereas all other treatments are oral.

Highlights from today's data show that:

  • Patients are more willing to consider and use self-injectable therapy than many physicians anticipate
  • Three-quarters (76%) of patients would consider using a self-injectable HIV therapy if their physician recommended it
  • Worryingly, only one quarter (28%) of patients who are potentially eligible for FUZEON had actually discussed this injectable option with their physicians
  • Only 10% of eligible patients were currently prescribed FUZEON, despite the fact that it is recommended in key international HIV treatment guidelines

This study also identifies some of the main reasons why many physicians may be reluctant to prescribe a treatment of proven efficacy and safety. The reasons include; the physicians' perception that patients would be reluctant to use a self-injectable therapy, the physicians' opinion that the patient would not be able to incorporate FUZEON into their lifestyle and the potential misconception that FUZEON is not appropriately recommended in guidelines.

"Physicians' best intentions in trying to match treatments t
'"/>

Contact: Kate Pogson
kate.pogson@ketchum.com
44-207-611-3552
Ketchum
18-Nov-2005


Page: 1 2

Related medicine news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New study counts the economic cost of persistent pain in Australia
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Most seniors now have drug coverage, U-M study shows
7. To gain muscle and lose fat, drink milk: study
8. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
9. Even older women at high risk have little interest in being tested for HIV, study finds
10. Metabolic study in mice could lead to good cholesterol boosters
11. Michigan-CDC study supports value of social restrictions during influenza pandemics

Post Your Comments:
(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... have a clot in their legs and are ... medication or undergo a minimally-invasive catheter-based clot removal ... difference in death rates between the two treatments, ... catheter procedure, according to a study by Temple ... a review of more than 90,000 cases nationwide., ...
(Date:7/21/2014)... The "viral reservoir" in which HIV can lie dormant ... earlier than previously thought, new animal research indicates. ... eradicate the AIDS-causing virus, said Harvard researchers working with ... presence of the viral reservoir remains the most significant ... HIV, known as HIV-1. "We found that the ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Western ... “Great College to Work For” by the Chronicle ... and also made the Honor Roll for the ... categories: Collaborative Governance, Compensation and Benefits, Confidence in ... Respect & Appreciation. , “Western University of Health ...
(Date:7/21/2014)... A new study suggests that potential help in lowering ... refrigerator. The study found that regular intake of ... supplements, may help ease the condition. Researchers looked ... probiotics and blood pressure. The studies involved a total ... pressure. People who consumed probiotics had an average ...
Breaking Medicine News(10 mins):Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
Cached News: